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Introduction: High altitude pulmonary edema is a non-cardiogenic form of pulmonary edema that develops in
unacclimatized individuals at altitudes over 2500 m. Early recognition of symptoms and immediate descent are
important for successful treatment. Despite early signs and symptoms of high altitude illness, many trekkers tend to
push themselves to the maximum limit. Some of them, such as the case reported here, choose to ascend on horse-
back which is extremely dangerous and can be fatal.
Case presentation: A 55 years of age Indian ethnic South African lady was emergency air-lifted from 4410 m
altitude in the Nepal Himalayas to Kathamandu (1300 m) with a suspected case of high altitude pulmonary edema.
She had continued ascending despite experiencing mild altitude symptoms at Namche (3440 m), and these
symptoms worsened considerably at Tengboche (3860 m). At the very start of her trek, just after Lukla (2800 m), she
suffered from sore throat, and had consequently begun a course of antibiotics (azithromycin) for a suspected throat
infection. She had planned to continue ascending on horse back to complete the trek, however her condition
deteriorated further and she had to be medically evacuated.
On admission to the clinic her axillary temperature was 99.4 F, blood pressure 120/60 mmHg, pulse rate 72/min,
respiratory rate of 25 breaths/min, and pulse oximeter showed saturation of 90% on room air at rest. Right sided
crackles on the axillary and posterior region were heard on chest auscultation. Heel to toe test showed no signs of
ataxia. The chest radiograph showed patchy infiltrates on the right side. An echocardiogram was done which revealed
a high pulmonary artery pressure of 50 mm of Hg. She was diagnosed as resolving high altitude pulmornay edema.
She was treated with bed rest, supplemental oxygen and sustained release nifedipine 20 mg (orally) twice a day. On
the third day her crackles had cleared significantly and repeat chest radiograph as shown showed remarkable
improvement. She felt much better. A repeat echocardiogram revealed a normal pulmonary artery pressure.
Conclusion: The case report highlights numerous points:
1) Many high altitude trekkers have invested significant time, money and physical efforts in in their ventures and are
determined to ascend despite early warning and illnesses. 2) Despite no history of altitude illnesses in previous altitude
exposure,inter-current illness (in this case a nonspecific respiratory tract infection) may contribute to the development
of high altitude pulmonary edema. 3) Continuing ascent using other transport means, whilst suffering from symptoms
of high altitude illness, worsens the condition and could be life threatening. 4) Acetazolamide does not prevent high
altitude pulmonary edema–perhaps more so in the cases that have inter-current illness. 5) Descent is the golden rule in
all altitude illnesses. Actually ‘descent’ is advised in any undiagnosed illness at high altitude among sojourners. 6) Finally,
an experienced guide who has mountain medicine training is essential. They can be crucial in noticing early signs and
symptoms of altitude illnesses to inform the client’s safety as in this case.
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Figure 1 Initial Chest x-ray showing pulmonary infiltrates in the
right lung especially in the right mid and lower lung zones
indicative of pulmonary edema.
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1) Continuing ascent using various transport means
(e.g. horse in this case) with high altitude illness
symptoms worsens condition and could be life
threatening.
2) Many high altitude trekkers have invested significant
time, money and physical efforts in in their ventures
and are determined to ascend despite early warning
and illnesses.
3) Despite no history of altitude illnesses in previous
altitude exposure,inter-current illness (in this case a
nonspecific respiratory tract infection) may contribute
to the development of high altitude pulmonary
edema.
4) Acetazolamide does not prevent high altitude
pulmonary edema–perhaps more so in the cases that
have inter-current illness.
5) Descent is the golden rule in all altitude illnesses.
Actually ‘descent’ is advised in any undiagnosed
illness at high altitude among sojourners.
6) Finally, an experienced guide who has mountain
medicine training is essential. They can be crucial in
noticing early signs and symptoms of altitude
illnesses to inform the client’s safety as in this case.
Background
High altitude pulmonary edema (HAPE) is a life threaten-
ing form of altitude illness [1,2]. Hypoxia induces uneven
pulmonary vasoconstriction leading to extravasation of
fluid from the pulmonary capillary beds leads to HAPE in
an unacclamitized individual [3]. It may occur without the
features of acute mountain sickness (AMS) such as head-
ache, tiredness, nausea and dizziness [1,2]. It is important
to recognize its early signs and symptoms as ascending
with such symptoms can quickly turn a relatively mild
altitude illness to severe pulmonary or cerebral edema. A
concurrent respiratory tract infection (RTI) is an add-
itional risk factor for HAPE [3].
Here we describe the development of HAPE in a
55 year old woman who was trekking in the Himalayas.
Case presentation
A 55 years of age Indian ethnic South African lady pre-
sented in a travel medicine clinic in Kathmandu for her
pre-hiking consultation. She was in good physical condi-
tion and had been on high-altitude trips before up to a
maximum of 4600 m in Machu Pichu (Peru) without
suffering from any symptoms of altitude illness.
This time she was trekking in the Khumbu region of
Nepal with a group of fellow South Africans. She started
her trek from an altitude of about 2800 m at Lukla and
was doing well except for a sore throat which had
started just after Lukla. She had begun a course ofantibiotics (azithromycin) for this suspected throat infec-
tion. At Namche Bazaar (3440 m) where she stayed for 2
nights, she started to experience mild headaches, weak-
ness, cough and nasal congestion but continued to go
up to Tengboche (3860 m). At Tengboche, she experi-
enced shortness of breath, bouts of coughing with sputum
and the fatigue worsened. However after a night’s stay at
Tengboche she continued to ascend to Dingboche
(4410 m) where she had extreme fatigue, vomiting (once
en route), coughing and difficulty breathing. She had no
fever. Most of these symptoms were mild at rest but wors-
ened upon the slightest exertion. She had started taking
acetazolamide 250 mg twice a day and continued her azi-
thromycin from Namche Bazaar. After the second night at
Dingboche the patient was feeling worse with what she
described as gurgling sounds arising from her chest and
yet she was determined to continue to ascend on horse-
back the following day with the rest of the group. How-
ever, her discerning guide noted the seriousness of the
condition and radioed his company in Kathmandu to ar-
range for a helicopter evacuation. She was transported by
helicopter from Dingboche to Kathmandu (1300 m) and
presented at the travel clinic. She felt improved after the
descent.
On admission to the clinic her axillary temperature was
99.4 F, blood pressure 120/60 mmHg, pulse rate 72/min,
respiratory rate of 25 breaths/min, and pulse oximeter
showed saturation of 90% on room air at rest. Right sided
crackles on the axillary and posterior region were heard
on chest auscultation. Heel to toe test showed no signs of
ataxia. The chest radiograph showed patchy infiltrates on
the right side (Figure 1). An echocardiogram was done
which revealed a high pulmonary artery pressure of
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tude pulmornay edema (HAPE). She was treated with bed
rest, supplemental oxygen and sustained release nifedipine
20 mg (orally) twice a day. On the third day her crackles
had cleared significantly and repeat chest radiograph as
shown showed remarkable improvement (Figure 2). She
felt much better. A repeat echocardiogram revealed a nor-
mal pulmonary artery pressure.
Discussion
This 55 year old woman continued to ascend despite
early symptoms of HAPE. Pushing herself to further alti-
tude on horseback (as planned) could have been fatal.
HAPE is a life-threatening non-cardiogenic pulmonary
edema that often develops in non-acclimatized individ-
uals going to high altitude. The prevalence of HAPE var-
ies depending upon the setting. The incidence of HAPE
among Himalayan trekkers and climbers in the Alps is
around 4% [4] depending on the rate of ascent. It typic-
ally occurs in the first 2–4 days after arrival at altitudes
above 2500 m [1,2]. A decrease in atmospheric partial
pressure of oxygen causes diminished arterial oxygen
saturation which further decreases during sleep, exercise
and respiratory tract infections [5,6]. HAPE results after
uneven hypoxic pulmonary vasoconstriction and in-
creased pulmonary vascular pressure causes alveolar
flooding with edema fluid [3]. Early signs and symptoms
of mountain sickness if recognized early can prevent the
development of severe forms when ascent is halted or
descent is made.
The patient described here had symptoms of cough,
headache, weakness and fatigue at an altitude of about
3400 m but assumed her symptoms to be due to non-
specific RTI (that started at the very beginning of her trekFigure 2 Repeat chest x- ray after 2 days showing rapid resolution
of the edema.in the Khumbu region at Lukla, 2800 m) and ascended
further using antibiotics (azithromycin for the RTI) and
acetazolamide for the prevention of acute mountain sick-
ness (AMS). Unfortunately her symptoms worsened with
shortness of breath at minimal exertion, extreme fatigue
and persistent cough-features consistent with HAPE.
Once altitude symptoms develop, they may quickly pro-
gress into serious conditions such as AMS, high altitude
cerebral edema (HACE) and HAPE, if appropriate mea-
sures are not taken-stop ascending, pharmacological treat-
ment and descent. Hence, it is important to emphasize
that a further gain of altitude is always detrimental with
altitude illness symptoms even while using acetazolamide.
Ascending further using alternative transport means, as
she had planned, can be catastrophic. Further, continued
ascent would have increased her hypoxemia, enhanced
her pulmonary artery pressures and worsened HAPE [3].
With further hypoxemia the subject could have developed
a more complex syndrome of altitude illnesses (AMS,
HAPE, and HACE) which could be fatal. It was correct
judgment on the part of her guide to descend immediately
in a helicopter.
Another factor that could have predisposed her to
HAPE is a concurrent respiratory tract infection. A high
rate of preceding RTI was found in children who devel-
oped HAPE [7]. Hence, this early inter-current illness
nonspecific RTI might have contributed to the develop-
ment of HAPE. Although HAPE is believed to be non-
inflammatory in nature, but rather related to stress failure
[8], a pre-existing inflammation may have caused the
subject to be more susceptible to the stress failure. Acet-
azolamide used here might have prevented AMS and im-
proved sleep quality [9,10] but does not seem to have
prevented HAPE. Acetazolamide is useful in preventing
and treating AMS but has no known role in HAPE [11].
Therefore, it becomes more important in such patients to
make a descent once the symptoms of HAPE are
recognized.
A prior history of HAPE is a significant predisposing
factor rendering an individual HAPE susceptible [3].
However as in this case, people who have not developed
HAPE in previous exposures to high altitude, may de-
velop HAPE if factors favouring increased capillary per-
meability are present such as infection [3].
It is important to recognize HAPE and not confuse it
with pneumonia. She was treated with oxygen and ni-
fedipine after arrival to the travel clinic. Her follow up
chest x-ray resolved completely after 2 days (Figure 1
and Figure 2). Chest x-ray changes of HAPE, unlike pneu-
monic consolidations, usually resolve in days with descent,
and oxygen is the main treatment [12]. If they have no
superadded infection, they do not require additional anti-
biotics [11,12]. In addition her high pulmonary artery pres-
sure is very suggestive of HAPE and not a consolidation.
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X-ray and the initial increased pulmonary artery pres-
sure are evidence of HAPE.
Other predisposing factors for HAPE include preexist-
ing conditions or anatomical abnormalities. Both of these
may cause increased pulmonary blood flow and/or intra-
vascular pressures, even at altitudes less than 2500 m [13].
One well-studiedexample of a condition leading to HAPE
is patent foramen ovale (PFO). The presence of PFO has
been found to be four times higher in HAPE-susceptible
individuals [3], and it is advisable that individuals with
HAPE have an echocardiography to rule out any anatom-
ical abnormalities of the heart.
Conclusions
Many individuals have invested significant time, money
and physical efforts to go high altitude. They will be de-
termined to ascend even at the cost of one’s health. Con-
tinuing ascent in the face of worsening symptom by
using other means of transport should always be dis-
couraged. Although acetazolamide is used for prophy-
laxis and treatment of acute mountain sickness (AMS),
it has no established role in the prevention and treat-
ment of HAPE. Descent is the golden rule in all high
altitude illnesses. It will be wise to descend for any un-
diagnosed illnesses at high altitude among sojourners.
Oxygen, needs to be administered, nifedipine can be
used as an adjunct, but descent remains an utmost pri-
ority. Hyperbaric bags e.g. Gamow Bag or Portable Alti-
tude Chamber are useful (especially in cases of HAPE
and HACE) to buy time for the rescue arrangements to
wait.
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